首页> 美国卫生研究院文献>Oxidative Medicine and Cellular Longevity >Retinal Diseases Associated with Oxidative Stress and the Effects of a Free Radical Scavenger (Edaravone)
【2h】

Retinal Diseases Associated with Oxidative Stress and the Effects of a Free Radical Scavenger (Edaravone)

机译:与氧化应激相关的视网膜疾病和自由基清除剂(依达拉奉)的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Oxidative stress plays a pivotal role in developing and accelerating retinal diseases including age-related macular degeneration (AMD), glaucoma, diabetic retinopathy (DR), and retinal vein occlusion (RVO). An excess amount of reactive oxygen species (ROS) can lead to functional and morphological impairments in retinal pigment epithelium (RPE), endothelial cells, and retinal ganglion cells (RGCs). Here we demonstrate that edaravone, a free radical scavenger, decreased apoptotic cell death, oxidative damage to DNA and lipids, and angiogenesis through inhibiting JNK and p38 MAPK pathways in AMD, glaucoma, DR, and RVO animal models. These data suggest that the therapeutic strategy for targeting oxidative stress may be important for the treatment of these ocular diseases, and edaravone may be useful for treating retinal diseases associated with oxidative stress.
机译:氧化应激在发展和加速视网膜疾病(包括与年龄相关的黄斑变性(AMD),青光眼,糖尿病性视网膜病变(DR)和视网膜静脉阻塞(RVO))中起关键作用。过量的活性氧(ROS)会导致视网膜色素上皮(RPE),内皮细胞和视网膜神经节细胞(RGC)的功能和形态受损。在这里,我们证明了依达拉奉,一种自由基清除剂,通过抑制AMD,青光眼,DR和RVO动物模型中的JNK和p38 MAPK途径,减少了凋亡细胞的死亡,对DNA和脂质的氧化损伤以及血管生成。这些数据表明,针对氧化应激的治疗策略可能对这些眼部疾病的治疗很重要,而依达拉奉可能对治疗与氧化应激相关的视网膜疾病有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号